Is Ozempic and Wegovy maker Novo Nordisk helping Americans save taxpayer money or ripping them off? The company's CEO is ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A key study used in securing FDA approval for Wegovy as a lifetime medication for weight loss was based on patients using the ...

The CEO of Novo Nordisk is set to appear before a Senate panel today to be grilled on the high cost of Ozempic and Wegovy, ...

This summary covers various health news briefs including AstraZeneca's breast cancer drug trial results, a bird flu case in ...

In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...

The World Health Organization (WHO) said on Monday that it has signed a $1.5 billion primary health financing platform with ...

The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...

As the Senate Committee on Health, Education, Labor and Pensions (HELP) gears up for a hearing tomorrow titled “Why Is Novo ...

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...

Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a ...